Des Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Desmin | |
|---|---|
| Gene Symbol | DES |
| Full Name | Desmin |
| Chromosome | 2q35 |
| NCBI Gene ID | 1674 |
| OMIM | 125660 |
| Ensembl ID | ENSG00000175084 |
| UniProt ID | P17661 |
| Protein Length | 470 amino acids |
| Molecular Weight | 53,350 Da |
| Associated Diseases | Myofibrillar Myopathy, Dilated Cardiomyopathy, Charcot-Marie-Tooth Disease, Neurodegeneration |
The DES gene encodes desmin, a muscle-specific type III intermediate filament protein that is a critical structural component of muscle cells[1]. Desmin forms a continuous network throughout the muscle fiber, connecting Z-discs to the sarcolemma, mitochondria, and nuclear envelope[2]. This network is essential for maintaining muscle fiber integrity, force transmission, and proper organization of the contractile apparatus[3].
Desmin is one of the earliest muscle-specific proteins expressed during development and is crucial for the formation and maintenance of myofibrils[4]. Beyond its structural role, desmin participates in cellular signaling, organelle positioning, and mechanotransduction[5].
The DES gene is located on chromosome 2q35 and consists of nine exons spanning approximately 8.4 kb of genomic DNA[6]. The gene encodes a 470-amino acid protein with a molecular weight of approximately 53 kDa[7]. The protein has a central alpha-helical rod domain flanked by non-helical head and tail domains, characteristic of intermediate filament proteins.
Desmin exhibits the classic intermediate filament protein architecture:
The protein forms coiled-coil dimers that assemble into tetramers and higher-order filaments in a phosphorylation-dependent manner[8].
Desmin provides structural support to muscle cells through:
Desmin participates in cellular signaling pathways:
Desmin is expressed in:
Desmin expression begins early in embryogenesis, with transcripts detectable in somites by embryonic day 9.5 in mice[11]. The protein becomes organized into a network during late embryonic development as myofibrils mature.
Myofibrillar myopathies are a group of genetically heterogeneous disorders characterized by progressive muscle weakness and myopathological features including desmin-positive aggregates[12]. DES mutations account for approximately 20-30% of MFM cases.
| Mutation | Domain | Phenotype | Year Described |
|---|---|---|---|
| R350P | Tail | MFM + cardiomyopathy | 1998 |
| E413K | Tail | MFM + cardiomyopathy | 2000 |
| A360P | Rod | MFM | 2005 |
| N342I | Tail | MFM + respiratory failure | 2007 |
Pathogenic mechanisms include:
DES mutations cause approximately 1-2% of familial dilated cardiomyopathy cases[14]. The cardiac phenotype often precedes skeletal muscle involvement.
Autosomal dominant intermediate neuropathy due to DES mutations has been described, characterized by:
While primarily a muscle disease, DES mutations can have neurological manifestations:
DES mutations lead to mitochondrial abnormalities:
Des Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Des Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Capetanaki Y, et al. (2015). Biochimica et Biophysica Acta. 2015. ↩︎
Herrmann H, et al. (2007). Nature Reviews Molecular Cell Biology. 2007. ↩︎
Geisler N, et al. (1992). European Journal of Biochemistry. 1992. ↩︎
Stromer MH. (1998). Seminars in Cell & Developmental Biology. 1998. ↩︎
Van Spaendonck-Zwarts KY, et al. (2011). Netherlands Heart Journal. 2011. ↩︎
Pekny M, et al. (2014). Handbook of Clinical Neurology. 2014. ↩︎
Schaart G, et al. (2001). Cell and Tissue Research. 2001. ↩︎
McNally EM, et al. (2013). Current Opinion in Cardiology. 2013. ↩︎
Winter L, et al. (2014). Acta Neuropathologica Communications. 2014. ↩︎
Wang X, et al. (2001). Proceedings of the National Academy of Sciences. 2001. ↩︎
Schoser BG, et al. (2017). Current Treatment Options in Neurology. 2017. ↩︎